Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Because retatrutide is not yet licensed in the UK, individuals are unlikely to encounter it outside of a formal clinical trial setting
The available studies concentrate on hair follicles and dermal papilla cells specifically
This stands in stark contrast to tesamorelin daily dosing requirement, creating a practical consideration for anyone evaluating the combination
## Availability Status: March 2026 - **FDA status:** Phase 3 clinical trials ongoing - **Expected approval timeline:** Potentially 2026-2027 - **Brand availability:** None yet - **Current access:** Compounding pharmacies (503A/503B) with valid prescription For a detailed breakdown of [retatrutide's FDA approval status and projected timeline](/guides/retatrutide-fda-approval-2026-timeline-status), see our dedicated tracker the date brand pricing becomes available depends directly on when retatrutide clears FDA review
they show inherited tendencies
